Version 2

Title: No association between the SARS-CoV-2 variants and mortality rates in the Eastern Mediterranean Region

Authors: Saad Omais¹, Samer Kharroubi², Hassan Zaraket^{3,4,#}

Affiliations:

1, Department of Biology, Faculty of Arts and Sciences, American University of Beirut, Beirut, Lebanon.

2, Department of Nutrition and Food Sciences, Faculty of Agricultural and Food Sciences, American University of Beirut, Beirut, Lebanon.

3, Faculty of Medicine, Center for Infectious Diseases Research, American University of Beirut, 1107 2020 Beirut, Lebanon.

4, Department of Experimental Pathology, Faculty of Medicine, Immunology & Microbiology, American University of Beirut, 1107 2020 Beirut, Lebanon.

Corresponding author: <u>hz34@aub.edu.lb</u>

Present/permanent address: Department of Experimental Pathology, Faculty of Medicine, Immunology & Microbiology, American University of Beirut, 1107 2020 Beirut, Lebanon

Keywords: SARS-CoV-2, whole genome, variants, case fatality rate, East Mediterranean Region

1 Abstract

2 As the novel coronavirus SARS-CoV-2 continues to spread in all countries, there is a growing interest in monitoring and understanding the impact of emerging strains on virus transmission 3 and disease severity. Here, we analyzed SARS-CoV-2 genomic sequences reported in the 4 Eastern Mediterranean Region (EMR) countries, as of 1 January 2021. The majority (~75%) of 5 these sequences originated from three out of 22 EMR countries, and 65.8% of all sequences 6 7 belonged to GISAID clades GR, GH, G and GV. A delay ranging between 30-150 days from 8 sample collection to sequence submission was observed across all countries, limiting the utility 9 of such data in informing public health policies. We identified ten common non-synonymous 10 mutations represented among SARS-CoV-2 in the EMR and several country-specific ones. Two substitutions, spike_D614G and NSP12_P323L, were predominantly concurrent in most 11 countries. While the single incidence of NSP12_P323L was positively correlated with higher 12 case fatality rates in EMR, no such association was established for the double (spike D614G and 13 NSP12_P323L) concurrent variant across the region. Our study identified critical data gaps in 14 EMR highlighting the importance of enhancing surveillance and sequencing capacities in the 15 region. 16

17 Introduction

In early October 2020, the World Health Organization (WHO) estimated that 10% of the global population has been infected with the novel coronavirus, SARS-CoV-2 (Keaten, 2020). Since its declaration as a pandemic seven months earlier, COVID-19 has inflicted substantial health and economic burden around the world (Fineberg, 2020; Ioannidis, 2020a). As of 22 January 2021, there have been over 96 million confirmed cases and 2 million deaths attributed to COVID-19 (WHO). Specifically, 5,461,398 confirmed cases (of whom 4,815,552 have recovered) and 130,079 deaths were reported in the Eastern Mediterranean Region (EMR) (WHO).

25 Prior to SARS-CoV-2 emergence, six human coronavirus (HCoV) strains were known to infect humans: two of which caused fatal respiratory diseases (SARS-CoV-1 and MERS-CoV), while 26 the remaining four circulate annually and cause 15-29% of all common colds (HCoV-229E, -27 OC43, -NL63 and -HKU1) (Su et al., 2016). SARS-CoV-2 gains access to the host cell by 28 binding to the human angiotensin-converting enzyme 2 (hACE2) through its spike (S) protein. 29 30 SARS-CoV-2 S receptor-binding domain (RBD) has a 10- to 20-fold higher hACE2 binding affinity than SARS-CoV-1 (Wrapp et al., 2020). Yet, SARS-CoV-2 RBD is less accessible such 31 that the overall S-hACE2 interaction is similar or weaker than that of SARS-CoV-1. 32 33 Nonetheless, the SARS-CoV-2 spike protein possesses a polybasic cleavage site making it accessible to furin protease which enhances cell entry (Shang et al., 2020). Similar to other beta-34 coronaviruses, SARS-CoV-2 has a positive-sense RNA genome that is around 30-kb in length 35 with six functional open reading frames (ORFs). ORFa and -b constitute nearly two-thirds of the 36 genome and produce 16 non-structural proteins (NSPs), including the RNA-dependent RNA 37 polymerase (RdRp or NSP12) and a helicase (NSP13). The structural nucleocapsid (N), 38

membrane (M), envelope (E), and S proteins are encoded by the remaining stretch of the RNA
genome along with other accessory proteins (Hartenian et al., 2020).

There has been a tremendous global surveillance effort to closely monitor SARS-CoV-2 41 circulating worldwide that enabled timely detection of emerging variants. SARS-CoV-2 evolves 42 at an estimated rate of around 6 x 10⁻⁴ nucleotides/genome/year (van Dorp et al., 2020a). 43 44 Numerous variants have emerged but only a handful of them have been fixated such as the 45 S_D614G that has prevailed globally. S_D614G was shown to alter infectivity and virulence of SARS-CoV-2 and was associated with an increase in mortality (Eaaswarkhanth et al., 2020; 46 47 Plante et al., 2020; van Dorp et al., 2020a; Vankadari, 2020; Wang et al., 2020). Specifically, Sallam et al. reported an increase in the incidence of S_D614G variant between February and 48 June 2020 in the Middle East and North Africa (Sallam et al., 2021). However, a detailed 49 50 genomic characterization of SARS-CoV-2 in EMR is still lacking. It also remains not clear whether the case fatality rates (CFRs) in EMR are associated with any of the prevailing SARS-51 CoV-2 variants. In this study, we analyzed SARS-CoV-2 whole-genome sequences collected in 52 53 EMR and examined the temporal and country-level associations between the predominant 54 variants and CFRs.

55 Methods

56 Sequence Retrieval and Analysis

SARS-CoV-2 sequences were downloaded from GISAID EpiCoVTM database (<u>Shu and</u>
<u>McCauley, 2017</u>) which were submitted by 1 January 2021 from EMR countries. These are
Afghanistan, Bahrain, Djibouti, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco,
Oman, Pakistan, Palestine, Qatar, Saudi Arabia, Somalia, Sudan, Syrian Arab Republic, Tunisia,

61 United Arab Emirates (UAE), and Yemen (http://www.emro.who.int/countries.html). Only 'high coverage' sequences were selected, i.e. "entries with <1% Ns and <0.05% unique amino acid 62 mutations (not seen in other sequences in the database) and no insertion/deletion unless verified 63 64 submitter". These were then analyzed by CoVsurver enabled by GISAID bv (https://www.gisaid.org/epiflu-applications/covsurver-mutations-app/) and compared 65 with reference strain hCoV-19/Wuhan/WIV04/2019 (accession number: EPI_ISL_402124). Sequence 66 metadata corresponding to age and gender were extracted from EpiCoVTM 'nextmeta' file for 67 sequences submitted as of 12 November 2020. For clade analysis, we used the Nextclade tool 68 69 from the Nextstrain project (https://clades.nextstrain.org/) (Hadfield et al., 2018) and GISAID clade designation provided by CoVsurver analysis. 70

71 *Country Data and Mortality Rate*

Data on population size, total COVID-19 cases, and total deaths were retrieved from the Worldometers website as of 22 January 2021 (https://www.worldometers.info/coronavirus/). Data on daily cases and deaths per country were extracted from WHO Coronavirus Disease (COVID-19) Dashboard (https://covid19.who.int/) (WHO). CFR was calculated and adjusted for a 13-day lag time from reporting to death, such that the denominator was designated as the cumulative cases from 13 days earlier, while the numerator totaled the cumulative deaths till 13 days earlier plus half the additional deaths recorded during the lag period (Wilson et al., 2020).

79 Statistical Analysis

The data were checked for completeness and entered into the Statistical Package for the Social Sciences (SPSS) software version 20 for Windows, which was later used for statistical analyses [IBM: Statistical Package for the Social Sciences. SPSS Statistics 2013, 20.]. Eight of the 15

83 EMR countries that have sequence data available were excluded from cross-country fatality correlations for the following reasons: Egypt had a relatively high CFR (5.9%) probably as a 84 result of the low number of reported cases (1073 cases per million) likely due to limited testing 85 86 capacity; Iraq, Pakistan, Tunisia, Lebanon, Kuwait, and Qatar had a relatively low sequence count each (<50, 1.5% of all sequences) (Figure 1A), Iran had only 18 complete sequences (>25 87 kbp) out of 104 sequences and was thus less comparable to other sequences (Supplementary 88 Figure 1). For the summary of the data, descriptive statistics were presented to summarize the 89 study variables of interest as counts and percentages across countries. Pie charts and bar plots 90 91 were used to chart comparison in count and percentages of variants across all countries. An independent t-test was used to chart the comparison of variants via gender (male vs female), 92 while one-way ANOVA was carried out for age distribution (0-9, 10-18, 19-49, 50-59, and >60). 93 Pearson's correlation coefficients were used to examine the association between variant 94 percentages and CFR for the seven countries considered in this study (Toyoshima et al., 2020). 95 For all analyses done, a *p*-value of less than 0.05 was used to detect statistical significance. 96

97 **Results**

We identified 3345 high-coverage SARS-CoV-2 genome sequences from EMR countries - no 98 99 sequences were available for Afghanistan, Djibouti, Libya, Somalia, Sudan, Syria, and Yemen. 100 Three countries accounted for ~75% of the sequence count overall – UAE (n=1233), Saudi Arabia (n=762) and Jordan (n=512) (Figure 1A). All but 5 EMR countries – Iran, Tunisia, Iraq, 101 102 Pakistan and Kuwait – had near-full length sequences of SARS-CoV-2 (Supplementary Figure 1). UAE had the highest sequence to population ratio (123.8 in 1 million), but also the highest 103 number of sequences per reported COVID-19 cases (45.5 per 10,000 cases) (Figure 1B, 1C). 104 When dates of collection were considered, none of the countries showed routine and consistent 105

sequencing; most sequences were collected before July (e.g. from UAE, Saudi Arabia, Oman) while only few countries (mainly Jordan, Bahrain and Morocco) reported sequences from the last three months (**Figure 1D**). Moreover, a significant delay between sample collection and sequence submission was observed across all countries (ranging 30-150 days), with no noticeable progress between first and last 100 days for the top three represented countries (**Figure 1E**).

112 Using CoVsurver from GISAID, amino acid substitutions were identified in each viral protein sequence and the top ten prevalent variants for each country were then plotted (excluding single-113 114 incidence variants) (Figure 2). In total, 2155 non-synonymous mutations were detected in EMR 115 countries, out of which ten common variants were found to be relatively most common (i.e. in \geq 8 EMR countries and > 2.5% of all sequences). These are: NSP12_P323L, S_D614G, 116 117 NS3_Q57H, N_R203K, N_G204R, N_S194L, NSP6_L37F, NSP2_V198L, NS8_L84S and N_S202N. Besides, many country-specific substitutions were detected (here defined as found in 118 119 3 other countries or less, and not listed in other countries' most common mutations). For 120 instance, NSP3_V1209I was found in 18% of UAE's sequences, Spike_Q957L in 80% of NSP12 M666I in 76% of Palestine's sequences (Figure 2). 121 Jordan's sequences and 122 NSP12 P323L and S D614G were predominantly detected in 10 out of 15 countries. S D614G was also dominant in Bahrain. In Kuwait and Iran, NSP6_L37F and NSP2_V198L were the most 123 frequently reported variants. 124

Next, we used the Nextclade tool from Nextstrain to assign clades (GISAID nomenclature) to the
sequences (Figure 3A) (GISAID, 2020). Of all sequences from EMR countries, 65.8% belonged
to the G (20A per Nextstrain clades), GR (20B), GH (20C) and GV (20A.EU1) clades, which
emerged following the introduction of the S_D614G variant (Figure 3B, (Alm et al., 2020)).

Moreover, these clades were almost exclusively represented as early as February and March in Saudi Arabia. In UAE, Jordan and Oman, clade distribution was heterogeneous with multiple clades cocirculating between February through November (**Figure 3C**).

132 For the sequence cohort submitted by 12 November 2020, more specimens were sequenced from males in the EMR (2.05:1 male-to-female in top four represented countries, independent t-test p 133 134 < 0.004): Saudi Arabia (4.44:1), UAE (2.25:1), Oman (1.42:1) and Egypt (1.49:1) (Figure 4A). 135 No statistically significant difference in gender distribution of the top represented SARS-CoV-2 variants were observed in these countries (independent t-test for all variants, p > 0.270) (Figure 136 137 **4B**). By analyzing the age distribution of the top variants in these countries, we observed a 138 statistically significant underrepresentation in the number of sequenced viruses from children (0-9 years) $(3.43\% \pm 1.21$ S.E.M.) and young adolescents (10-18 years) (2.26% \pm 1.16), while 139 140 adults (19-49) were more represented (62.5% \pm 8.84) (ANOVA; F = 73.4, p = 1.15E-9) (Figure 4C). For the three remaining age categories (19-49, 50-59 and >60 years), we report no 141 statistically significant difference in the occurrence of the Wuhan-like or any of the identified 142 143 variants (multivariate ANOVA for all variants, F < 0.906, p > 0.487) (Figure 4D).

We next sought to determine whether a correlation exists between the incidence of the ten most 144 145 common variants and countries' CFRs. Only seven countries were included in this analysis -UAE, Saudi Arabia, Jordan, Oman, Bahrain, Palestine and Morocco – where only NSP12_P323L 146 out of the ten variants was significantly correlated with an increase in CFR (R=0.883, P=0.008) 147 (Figure 5). However, consistent with previous studies (Ilmjärv et al., 2020; Kannan et al., 2020), 148 we confirm that NSP12_P323L seems to have quickly co-evolved following S_D614G 149 introduction, as they are more often co-detected among SARS-CoV-2 genome sequences 150 151 (Figure 6A). This double variant 'D614G & P323L' is found to be evenly represented among 152 different age groups in UAE, Saudi Arabia, Oman and Egypt (for sequences submitted by 12 153 November) (Figure 6B). After repeating the correlation analysis while accounting for the single versus double occurrence of D614G and P323L, we found that neither single nor double variants 154 155 were significantly correlated with CFR. The P323L-single variant was mainly detected in Saudi Arabia (19% of it sequences) and among 0.5% sequences reported from UAE, while in the other 156 countries it was exclusively co-detected with D614G. As such, we suggest that the earlier 157 correlation of NSP12 P323L is likely the result of considering single- and double-variants as one 158 group, specifically in Saudi Arabia. However, when such distinction was made, no correlation 159 160 with higher CFR was reported in either group (Figure 6C).

161 Since sequences of UAE, Saudi Arabia and Oman were dominantly collected before September and those of Jordan and Bahrain were collected afterwards (Figure 1D), we repeated our 162 163 analysis but this time accounting for the cumulative incidence of the 'D614G & P323L' double variant and the CFR at the end of each month. We observed no significant association between 164 these two variables from March through September (Supplementary Figure 2). To further 165 166 investigate this correlation, we considered the cumulative monthly incidence of 'D614G & 167 P323L' and the monthly CFRs (Figure 7A): while UAE showed a significantly negative 168 correlation between 'D614G & P323L' incidence and the monthly CFR (R=-0.830, P=0.021), Saudi Arabia showed a significantly positive correlation (R=0.909, P=0.012). Meanwhile, Jordan 169 and Oman had no significant associations (R=-0.101, P=0.849; R=0.921, P=0.079 respectively) 170 171 (Figure 7B). This suggests that by accounting for the change in CFR for each country with time 172 the correlation between 'D614G & P323L' incidence and higher fatality does not necessarily 173 hold true contrary to previous findings (Becerra-Flores and Cardozo, 2020; Eaaswarkhanth et al., 174 2020; Toyoshima et al., 2020).

175 Discussion

176 In this study, we analyzed whole-genome sequences of SARS-CoV-2 collected in the EMR 177 countries. Significant data gaps are notable, whereby sequences were lacking for seven EMR 178 countries – the majority of which are in war conflict zones (e.g., Syria, Libya, and Yemen (Daw, 2020)). In general, large disparities in the availability of sequences are observed across EMR. 179 180 Only five countries reported \geq 150 sequences spanning the first year of the pandemic, with UAE, 181 Saudi Arabia and Jordan exceeding 500 sequence submissions. These data gaps highlight the challenges for monitoring the pandemic in developing countries particularly in conflict zones. It 182 183 also emphasizes the importance of building regional sequencing capacities for timely and 184 continuous monitoring of viral evolution during the pandemic (Al Saidi et al., 2020; Salameh, 2020). 185

186 Despite the diversity in the substitutions detected across countries, only a handful of variants predominated. For instance, a mere 9 out of 945 non-synonymous mutations (0.95%) in UAE 187 188 and 6 out of 421 mutations (1.4%) in Saudi Arabia were detected in more than 10% of the respective total of sequences (Figure 2). This suggests that consistent with other studies, most 189 SARS-CoV-2 mutations are neutral or deleterious (van Dorp et al., 2020a). Although a random 190 191 founder's effect cannot be ruled out, the increased frequency of certain substitutions might be attributable to a fitness advantage (Callaway, 2020; Grubaugh et al., 2020; Kannan et al., 2020; 192 Plante et al., 2020; Yurkovetskiy et al., 2020; Zhang et al., 2020). For instance, the S_D614G 193 was found to predominate all viral strains globally (78% of sequences by May 2020) and was 194 associated with increased viral loads in the upper respiratory tract of COVID-19 patients (Korber 195 et al., 2020). Along the same line, Plante et al. recently demonstrated that S_D614G enhanced 196 viral replication and infectivity of SARS-CoV-2 in human lung epithelial cells and primary 197

198 human airway tissues and increased infectious virus loads in hamsters' nasal cavities (Plante et 199 al., 2020). Hou et al. further showed that the S D614G variant displayed faster transmission and 200 increased competitive fitness *in vivo* compared to wild-type virus in hamsters (Hou et al., 2020). 201 These findings were also confirmed in hACE2 knock-in mice as well as in ferrets (Zhou et al., 2021). On a molecular level, S_D614G allows for more efficient infectivity by shifting the spike 202 protein to a more 'open' conformation that is more favorable of ACE2 binding (Yurkovetskiy et 203 al., 2020). Interestingly, however, a recent analysis by van Dorp et al. could not identify any 204 single recurrent mutation, including the S_D614G, to be convincingly associated with increased 205 206 viral transmission in humans (van Dorp et al., 2020b).

207 Several studies reported a positive correlation between S_D614G incidence and mortality (CFR) (Becerra-Flores and Cardozo, 2020; Eaaswarkhanth et al., 2020; Toyoshima et al., 2020). 208 209 However, a more recent study of 25,000 SARS-CoV-2 sequences in the United Kingdom did not 210 associate the incidence of this mutation with higher COVID-19 mortality or with clinical severity in patients (Volz et al., 2021). Similarly, Korber et al. did no find an association between 211 212 S_D614G and increased disease severity or hospitalization (Korber et al., 2020). In our sequence 213 set, we saw no association between S D614G with CFRs of select EMR countries. Instead, the 214 increasing incidence of NSP12 P323L (of the ten most common substitutions), when considered alone, was correlated with a higher mortality rate. However, our data as well as others' (Ilmjärv 215 et al., 2020; Kannan et al., 2020) show that the NSP12 P323L and S D614G are frequently 216 217 coupled in most sequences, suggesting co-evolution of these variants (Figure 6A). Therefore, we 218 assessed the combined effect of the 'D614G & P323L' double variant on mortality. We found no correlation between the cumulative incidence of the 'D614G & P323L' variant and CFRs in the 219 220 EMR countries, consistent with earlier observations that found no association between 'D614G

& P323L' and deaths per million, CFR and patient status (Ilmjärv et al., 2020). In contrast to the 221 222 well-studied S_D614G, the effect of NSP12_P323L on viral fitness is much less understood 223 (Hillen et al., 2020; Pachetti et al., 2020). One study speculated that it negatively impacts NSP8's 224 association with RdRp leading to an attenuated polymerase activity (Ilmjärv et al., 2020), while another suggested that it enhances hydrophobic NSP8-RdRp interactions leading to improved 225 226 processivity of RdRp and enhanced viral replication overall (Kannan et al., 2020). In all cases, it is speculated that the 'epidemiological success' of the G, GH, GR and GV lineages could be 227 attributed to the combined viral fitness advantage conferred by both NSP12_P323L and 228 229 S D614G (Ilmjärv et al., 2020).

230 Considering the limitations due to the discrepant number of sequences available (as mentioned above) or to country-specific variations in managing the COVID-19 pandemic (such as testing 231 232 capacity, age stratification, enforcing/relaxing lockdown policies, etc.), we assessed the association of 'D614G & P323L' incidence with CFR within each of the top four represented 233 countries over time. Interestingly, we found a significantly negative correlation between 'D614G 234 235 & P323L' incidence and COVID-19 CFR in UAE, but an otherwise positive correlation in Saudi 236 Arabia (Figure 7B). This suggests that the reported correlation between these variants and 237 increased CFR might be a mere coincidence rather than true causation. Noteworthy, our method of calculating daily/monthly CFR is credited for accounting for a 13-day lag between cumulative 238 cases and deaths (Wilson et al., 2020). Yet, it overestimates the case fatality risk early on in the 239 pandemic (Ge and Sun, 2020), a limitation that would apply to our final analysis. Then again, 240 241 considering the overwhelming discrepancy in fatality correlations between countries, it is unlikely that early bias in CFR estimation would have altered our conclusion. Additionally, a 242 243 more accurate method to estimate COVID-19 mortality would be the infection fatality rate (IFR),

inferred from seroprevalence studies. However, such data is only available for Iran, Pakistan, and
Qatar out of all EMR countries according to a recent WHO review (<u>Ioannidis, 2020b</u>).

246 Other genomic mutations were associated with milder disease, such as a major deletion ($\Delta 382$; 247 nucleotide positions: 27,848 to 28,229), which results in truncated ORF7b and arrested transcription of ORF8 (Su et al., 2020). Patients infected with the SARS-CoV-2 \triangle 382 variant 248 249 had less systemic release of proinflammatory cytokines and better clinical outcomes (i.e. lower 250 frequency of hypoxia requiring supplemental oxygen) than wild-type (Young et al., 2020). This 251 variant, however, was not present in any of our sequence cohort. Moreover, an S_ N439K variant 252 was reported to enhance spike binding to its protein hACE2, resulting in immune escape from a 253 panel of neutralizing monoclonal antibodies (Thomson et al., 2021). We detected only one 254 sequence carrying this mutation from Morocco (EPI_ISL_728353).

255 On a final note, the COVID-19 pandemic cannot be viewed in the absence of other respiratory viruses, especially in view of the increased concerns regarding a 'Twindemic' (Uyeki et al., 256 257 2020; Adlhoch et al., 2021). In the case of influenza, few cases were reported in EMR countries 258 in 2020-21 season (<20 positive specimens per week; GISRS report), a pattern that was 259 established worldwide (Jones, 2020). Previous studies from the United States and Australia 260 reported a co-infection rate ranging from 2% to 6.9% between SARS-CoV-2 and other respiratory viruses including rhinovirus/enterovirus, RSV, other coronaviruses, and influenza 261 virus (Kim et al., 2020; Kim et al., 2021). Elghoudi et al. reported an incidence of 3.1% (9/288) 262 respiratory co-infections with SARS-CoV-2 in children and young adolescents in a hospital in 263 264 UAE (Elghoudi et al., 2020). In addition to co-infections with respiratory viruses a study from 265 Pakistan reported a relatively high incidence of co-infections between SARS-CoV-2 and the endemic dengue virus -25% (5/20) of studied samples (Saddique et al., 2020). A meta-analysis 266

study estimated that while 3% of COVID-19 patients (out of 1014 patients from 16 studies) had a confirmed viral co-infection, there was no significant increase in hospitalization or ICU admission in the co-infected cohort (Lansbury et al., 2020). Overall, the incidence of respiratory viral co-infections is low and may not be considered a key factor associated with mortality.

Our analysis reveals the diversity of SARS-CoV-2 in EMR and emphasizes the importance of considering temporal incidence and concurrent mutations in disease correlations. Our study is limited by the relatively low number of specimens sequenced per country spanning ten months of COVID-19 pandemic. There is a critical need for continuous and consistent surveillance of SARS-CoV-2 genomic variations in the EMR region.

276

277 Acknowledgments

S.O. is the recipient of a joint doctoral fellowship from the American University of Beirut (AUB) and the National Council for Scientific Research of Lebanon (CNRS-L). We gratefully acknowledge the authors from the originating laboratories responsible for obtaining the specimens, as well as the submitting laboratories where the genome data were generated and shared via GISAID, on which this research is based (a detailed list of authors and laboratories can be found in the supplementary material). We also thank Dr. Colin A. Smith and Dr. Heinrich zu Dohnna (Biology department, American University of Beirut) for their valuable comments.

285 **Competing Interests:** The authors declare no conflicts of interest.

Funding: This research did not receive any specific grant from funding agencies in the public,commercial, or not-for-profit sectors.

288

289 **References**

- Adlhoch, C., Mook, P., Lamb, F., Ferland, L., Melidou, A., Amato-Gauci, A.J., Pebody, R. and
 European Influenza Surveillance, N., 2021. Very little influenza in the WHO European
 Region during the 2020/21 season, weeks 40 2020 to 8 2021. Euro Surveill 26.
- Al Saidi, A.M.O., Nur, F.A., Al-Mandhari, A.S., El Rabbat, M., Hafeez, A. and Abubakar, A.,
 2020. Decisive leadership is a necessity in the COVID-19 response. The Lancet 396, 295 298.
- Alm, E., Broberg, E.K., Connor, T., Hodcroft, E.B., Komissarov, A.B., Maurer-Stroh, S.,
 Melidou, A., Neher, R.A., O'Toole, A., Pereyaslov, D., laboratories, W.H.O.E.R.s.,
 group, G.E., laboratories, W.H.O.E.R.s. and group*, G.E., 2020. Geographical and
 temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to
 June 2020. Euro Surveill 25.
- Becerra-Flores, M. and Cardozo, T., 2020. SARS-CoV-2 viral spike G614 mutation exhibits
 higher case fatality rate. Int J Clin Pract 74, e13525.
- Callaway, E., 2020. The coronavirus is mutating does it matter? Nature 585, 174-177.
- Daw, M.A., 2020. Corona virus infection in Syria, Libya and Yemen; an alarming devastating
 threat. Travel Med Infect Dis 37, 101652.
- Eaaswarkhanth, M., Al Madhoun, A. and Al-Mulla, F., 2020. Could the D614 G substitution in
 the SARS-CoV-2 spike (S) protein be associated with higher COVID-19 mortality?
 International Journal of Infectious Diseases.
- Elghoudi, A., Aldhanhani, H., Ghatasheh, G., Sharif, E. and Narchi, H., 2020. Covid-19 in
 Children and Young Adolescents in Al Ain, United Arab Emirates- a Retrospective
 Cross-Sectional Study. Front Pediatr 8, 603741.
- 312 Fineberg, H.V., 2020. The Toll of COVID-19. JAMA 324, 1502-1503.
- Ge, Y. and Sun, S., 2020. Estimation of Coronavirus Disease Case-Fatality Risk in Real Time.
 Emerg Infect Dis 26, 1922-1923.
- GISAID, 2020. Clade and lineage nomenclature aids in genomic epidemiology studies of active
 hCoV-19 viruses. GISAID, Munich.
- Grubaugh, N.D., Hanage, W.P. and Rasmussen, A.L., 2020. Making Sense of Mutation: What
 D614G Means for the COVID-19 Pandemic Remains Unclear. Cell 182, 794-795.
- Hadfield, J., Megill, C., Bell, S.M., Huddleston, J., Potter, B., Callender, C., Sagulenko, P.,
 Bedford, T. and Neher, R.A., 2018. Nextstrain: real-time tracking of pathogen evolution.
 Bioinformatics 34, 4121-4123.
- Hartenian, E., Nandakumar, D., Lari, A., Ly, M., Tucker, J.M. and Glaunsinger, B.A., 2020. The
 molecular virology of coronaviruses. J Biol Chem 295, 12910-12934.
- Hillen, H.S., Kokic, G., Farnung, L., Dienemann, C., Tegunov, D. and Cramer, P., 2020.
- 325 Structure of replicating SARS-CoV-2 polymerase. Nature 584, 154-156.
- Hou, Y.J., Chiba, S., Halfmann, P., Ehre, C., Kuroda, M., Dinnon, K.H., 3rd, Leist, S.R.,
 Schafer, A., Nakajima, N., Takahashi, K., Lee, R.E., Mascenik, T.M., Graham, R.,
- 328 Edwards, C.E., Tse, L.V., Okuda, K., Markmann, A.J., Bartelt, L., de Silva, A., Margolis,
- D.M., Boucher, R.C., Randell, S.H., Suzuki, T., Gralinski, L.E., Kawaoka, Y. and Baric,
- R.S., 2020. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science.
- Ilmjärv, S., Abdul, F., Acosta-Gutiérrez, S., Estarellas, C., Galdadas, I., Casimir, M.,
- Alessandrini, M., Gervasio, F.L. and Krause, K.-H., 2020. Epidemiologically most

334 successful SARS-CoV-2 variant: concurrent mutations in RNA-dependent RNA 335 polymerase and spike protein. medRxiv. Ioannidis, J.P.A., 2020a. Global perspective of COVID-19 epidemiology for a full-cycle 336 337 pandemic. Eur J Clin Invest, e13423. Ioannidis, J.P.A., 2020b. Infection fatality rate of COVID-19 inferred from seroprevalence data. 338 Bulletin of the World Health Organization. 339 340 Jones, N., 2020. How COVID-19 is changing the cold and flu season. Nature 588, 388-390. Kannan, S.R., Spratt, A.N., Quinn, T.P., Heng, X., Lorson, C.L., Sonnerborg, A., Byrareddy, 341 S.N. and Singh, K., 2020. Infectivity of SARS-CoV-2: there Is Something More than 342 343 D614G? J Neuroimmune Pharmacol. Keaten, J., 2020. WHO: 10% of world's people might have had COVID-19, Telegraph - Herald. 344 Dubuque, Iowa. 345 Kim, D., Quinn, J., Pinsky, B., Shah, N.H. and Brown, I., 2020. Rates of Co-infection Between 346 347 SARS-CoV-2 and Other Respiratory Pathogens. JAMA 323, 2085-2086. Kim, K.W., Deveson, I.W., Pang, C.N.I., Yeang, M., Naing, Z., Adikari, T., Hammond, J.M., 348 349 Stevanovski, I., Beukers, A.G., Verich, A., Yin, S., McFarlane, D., Wilkins, M.R., Stelzer-Braid, S., Bull, R.A., Craig, M.E., van Hal, S.J. and Rawlinson, W.D., 2021. 350 Respiratory viral co-infections among SARS-CoV-2 cases confirmed by virome capture 351 sequencing. Sci Rep 11, 3934. 352 353 Korber, B., Fischer, W.M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E.E., Bhattacharya, T., Foley, B., Hastie, K.M., Parker, M.D., Partridge, D.G., 354 Evans, C.M., Freeman, T.M., de Silva, T.I., Sheffield, C.-G.G., McDanal, C., Perez, L.G., 355 Tang, H., Moon-Walker, A., Whelan, S.P., LaBranche, C.C., Saphire, E.O. and 356 Montefiori, D.C., 2020. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G 357 Increases Infectivity of the COVID-19 Virus. Cell 182, 812-827 e19. 358 Lansbury, L., Lim, B., Baskaran, V. and Lim, W.S., 2020. Co-infections in people with COVID-359 19: a systematic review and meta-analysis. J Infect 81, 266-275. 360 Pachetti, M., Marini, B., Benedetti, F., Giudici, F., Mauro, E., Storici, P., Masciovecchio, C., 361 Angeletti, S., Ciccozzi, M., Gallo, R.C., Zella, D. and Ippodrino, R., 2020. Emerging 362 SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase 363 variant. J Transl Med 18, 179. 364 Plante, J.A., Liu, Y., Liu, J., Xia, H., Johnson, B.A., Lokugamage, K.G., Zhang, X., Muruato, 365 A.E., Zou, J., Fontes-Garfias, C.R., Mirchandani, D., Scharton, D., Bilello, J.P., Ku, Z., 366 An, Z., Kalveram, B., Freiberg, A.N., Menachery, V.D., Xie, X., Plante, K.S., Weaver, 367 S.C. and Shi, P.Y., 2020. Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 368 Saddigue, A., Rana, M.S., Alam, M.M., Ikram, A., Usman, M., Salman, M., Farval, R., Massab, 369 U., Bokhari, H., Mian, M.S., Israr, A. and Safiullah, 2020. Emergence of co-infection of 370 371 COVID-19 and dengue: A serious public health threat. J Infect 81, e16-e18. Salameh, P., 2020. COVID-19 in the Eastern Mediterranean Region: testing frequency, 372 cumulative cases and mortality analysis. East Mediterr Health J 26, 1005-1010. 373 Sallam, M., Ababneh, N.A., Dababseh, D., Bakri, F.G. and Mahafzah, A., 2021. Temporal 374 increase in D614G mutation of SARS-CoV-2 in the Middle East and North Africa. 375 Heliyon 7, e06035. 376 Shang, J., Wan, Y., Luo, C., Ye, G., Geng, Q., Auerbach, A. and Li, F., 2020. Cell entry 377 mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A 117, 11727-11734. 378

- Shu, Y. and McCauley, J., 2017. GISAID: Global initiative on sharing all influenza data from
 vision to reality. Euro Surveill 22.
- Su, S., Wong, G., Shi, W., Liu, J., Lai, A.C.K., Zhou, J., Liu, W., Bi, Y. and Gao, G.F., 2016.
 Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends
 Microbiol 24, 490-502.
- Su, Y.C.F., Anderson, D.E., Young, B.E., Linster, M., Zhu, F., Jayakumar, J., Zhuang, Y.,
 Kalimuddin, S., Low, J.G.H., Tan, C.W., Chia, W.N., Mak, T.M., Octavia, S., Chavatte,
 J.M., Lee, R.T.C., Pada, S., Tan, S.Y., Sun, L., Yan, G.Z., Maurer-Stroh, S., Mendenhall,
 I.H., Leo, Y.S., Lye, D.C., Wang, L.F. and Smith, G.J.D., 2020. Discovery and Genomic
 Characterization of a 382-Nucleotide Deletion in ORF7b and ORF8 during the Early
 Evolution of SARS-CoV-2. mBio 11.
- Thomson, E.C., Rosen, L.E., Shepherd, J.G., Spreafico, R., da Silva Filipe, A., Wojcechowskyj,
 J.A., Davis, C., Piccoli, L., Pascall, D.J., Dillen, J., Lytras, S., Czudnochowski, N., Shah,
 R., Meury, M., Jesudason, N., De Marco, A., Li, K., Bassi, J., O'Toole, A., Pinto, D.,
- 393 Colquhoun, R.M., Culap, K., Jackson, B., Zatta, F., Rambaut, A., Jaconi, S., Sreenu,
- V.B., Nix, J., Zhang, I., Jarrett, R.F., Glass, W.G., Beltramello, M., Nomikou, K.,
- 395 Pizzuto, M., Tong, L., Cameroni, E., Croll, T.I., Johnson, N., Di Iulio, J., Wickenhagen,
- A., Ceschi, A., Harbison, A.M., Mair, D., Ferrari, P., Smollett, K., Sallusto, F.,
- 397 Carmichael, S., Garzoni, C., Nichols, J., Galli, M., Hughes, J., Riva, A., Ho, A., Schiuma,
- 398 M., Semple, M.G., Openshaw, P.J.M., Fadda, E., Baillie, J.K., Chodera, J.D.,
- Investigators, I.C., Consortium, C.-G.U., Rihn, S.J., Lycett, S.J., Virgin, H.W., Telenti,
- A., Corti, D., Robertson, D.L. and Snell, G., 2021. Circulating SARS-CoV-2 spike
 N439K variants maintain fitness while evading antibody-mediated immunity. Cell 184, 1171-1187 e20.
- Toyoshima, Y., Nemoto, K., Matsumoto, S., Nakamura, Y. and Kiyotani, K., 2020. SARS-CoV 2 genomic variations associated with mortality rate of COVID-19. J Hum Genet.
- Uyeki, T.M., Santoli, J. and Jernigan, D.B., 2020. Preparing for the 2020-2021 Influenza Season.
 JAMA 324, 2318-2319.
- van Dorp, L., Acman, M., Richard, D., Shaw, L.P., Ford, C.E., Ormond, L., Owen, C.J., Pang, J.,
 Tan, C.C.S., Boshier, F.A.T., Ortiz, A.T. and Balloux, F., 2020a. Emergence of genomic
 diversity and recurrent mutations in SARS-CoV-2. Infect Genet Evol 83, 104351.
- van Dorp, L., Richard, D., Tan, C.C.S., Shaw, L.P., Acman, M. and Balloux, F., 2020b. No
 evidence for increased transmissibility from recurrent mutations in SARS-CoV-2. Nat
 Commun 11, 5986.
- Vankadari, N., 2020. Overwhelming mutations or SNPs of SARS-CoV-2: A point of caution.
 Gene 752, 144792.
- Volz, E., Hill, V., McCrone, J.T., Price, A., Jorgensen, D., O'Toole, A., Southgate, J., Johnson,
 R., Jackson, B., Nascimento, F.F., Rey, S.M., Nicholls, S.M., Colquhoun, R.M., da Silva
- 417 Filipe, A., Shepherd, J., Pascall, D.J., Shah, R., Jesudason, N., Li, K., Jarrett, R.,
- 418 Pacchiarini, N., Bull, M., Geidelberg, L., Siveroni, I., Consortium, C.-U., Goodfellow, I.,
- 419 Loman, N.J., Pybus, O.G., Robertson, D.L., Thomson, E.C., Rambaut, A. and Connor,
- 420 T.R., 2021. Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on
- 421 Transmissibility and Pathogenicity. Cell 184, 64-75 e11.
- Wang, C., Liu, Z., Chen, Z., Huang, X., Xu, M., He, T. and Zhang, Z., 2020. The establishment
 of reference sequence for SARS-CoV-2 and variation analysis. J Med Virol 92, 667-674.

- WHO. Eastern Mediterranean Regional Office COVID-19 Dashboard (2021).
 http://www.emro.who.int/index.html. Last Accessed: Jan 22 2021.
- WHO. WHO Coronavirus Disease (COVID-19) Dashboard (2021). <u>https://covid19.who.int/</u>.
 Last Accessed: Jan 22 2021.
- WHO. WHO Global Influenza Surveillance and Response System (GISRS). Number of
 Specimens Positive for Influenza by Subtype, Eastern Mediterranean Region of WHO
 (2021) <u>https://apps.who.int/flumart/Default?ReportNo=3&WHORegion</u>= Last Accessed:
 Mar 21 2021.
- Wilson, N., Kvalsvig, A., Barnard, L.T. and Baker, M.G., 2020. Case-Fatality Risk Estimates for
 COVID-19 Calculated by Using a Lag Time for Fatality. Emerg Infect Dis 26, 1339 1441.
- Wrapp, D., Wang, N., Corbett, K.S., Goldsmith, J.A., Hsieh, C.L., Abiona, O., Graham, B.S. and
 McLellan, J.S., 2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion
 conformation. Science 367, 1260-1263.
- Young, B.E., Fong, S.W., Chan, Y.H., Mak, T.M., Ang, L.W., Anderson, D.E., Lee, C.Y.,
 Amrun, S.N., Lee, B., Goh, Y.S., Su, Y.C.F., Wei, W.E., Kalimuddin, S., Chai, L.Y.A.,
 Pada, S., Tan, S.Y., Sun, L., Parthasarathy, P., Chen, Y.Y.C., Barkham, T., Lin, R.T.P.,
 Maurer-Stroh, S., Leo, Y.S., Wang, L.F., Renia, L., Lee, V.J., Smith, G.J.D., Lye, D.C.
 and Ng, L.F.P., 2020. Effects of a major deletion in the SARS-CoV-2 genome on the
 severity of infection and the inflammatory response: an observational cohort study.
 Lancet 396, 603-611.
- Yurkovetskiy, L., Wang, X., Pascal, K.E., Tomkins-Tinch, C., Nyalile, T.P., Wang, Y., Baum,
 A., Diehl, W.E., Dauphin, A., Carbone, C., Veinotte, K., Egri, S.B., Schaffner, S.F.,
 Lemieux, J.E., Munro, J.B., Rafique, A., Barve, A., Sabeti, P.C., Kyratsous, C.A.,
 Dudkina, N.V., Shen, K. and Luban, J., 2020. Structural and Functional Analysis of the
- 449 D614G SARS-CoV-2 Spike Protein Variant. Cell 183, 739-751 e8.
- Zhang, L., Jackson, C.B., Mou, H., Ojha, A., Peng, H., Quinlan, B.D., Rangarajan, E.S., Pan, A.,
 Vanderheiden, A., Suthar, M.S., Li, W., Izard, T., Rader, C., Farzan, M. and Choe, H.,
 2020. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and
 infectivity. Nat Commun 11, 6013.
- Zhou, B., Thi Nhu Thao, T., Hoffmann, D., Taddeo, A., Ebert, N., Labroussaa, F., Pohlmann, A.,
 King, J., Steiner, S., Kelly, J.N., Portmann, J., Halwe, N.J., Ulrich, L., Trueb, B.S., Fan,
 X., Hoffmann, B., Wang, L., Thomann, L., Lin, X., Stalder, H., Pozzi, B., de Brot, S.,
 Jiang, N., Cui, D., Hossain, J., Wilson, M., Keller, M., Stark, T.J., Barnes, J.R., Dijkman,
 R., Jores, J., Benarafa, C., Wentworth, D.E., Thiel, V. and Beer, M., 2021. SARS-CoV-2
 spike D614G change enhances replication and transmission. Nature.
- 460

461

462 Figure Legends

- **Figure 1. Distribution of SARS-CoV-2 sequences in EMR countries.** (A) Pie chart showing
- number of available sequences as of 1 January 2021. (B) Histogram showing ratio of sequences
- 465 per million population. (C) Histogram showing ratio of sequences per 10,000 confirmed cases of
- 466 SARS-CoV-2. (D) Temporal distribution of sequence collection in EMR countries from January
- through December 2020. (E) Averages of delay in sequence submission (in days) of available
- EMR countries. For UAE, Saudi Arabia and Jordan, only the first and last 100 collected
- sequences were considered. Error bars represent standard deviation.
- 470 Figure 1. Common SARS-CoV-2 substitutions detected in EMR countries. Bar graphs
- showing percentages of most prevalent SARS-CoV-2 variants per country, excluding single-
- incidence variants. Colored are the top ten most represented substitutions; in black are country-
- 473 specific ones.
- 474 Figure 2. EMR sequences are dominantly distributed in G, GR and GH GISAID clades. (A)
- Phylogenetic tree of GISAID clades plotted over time. Red arrow points to the introduction of
- 476 S_D614G, marking the emergence of G, GR and GH clades (reproduced from Nextstrain [Ref.
- 17]. (B) Clade distribution of all 3345 sequences. (C) Temporal distribution of sequences as
- 478 clades in the top four represented countries.
- 479 Figure 4. Gender and age distribution of SARS-CoV-2 variants in four EMR countries.
- 480 Gender distribution of (A) sequences of Saudi Arabia, UAE, Oman and Egypt and (B) select top
- 481 most frequent variants of these countries. (C) Age groups distribution of sequences from four
- 482 EMR countries and (D) of most frequent variants. Sequences in this figure are as of 12
- November 2020 due to the inability to extract demographics from metafiles after this date.
- 484 Figure 5. Only NSP12_P323L of the ten most common SARS-CoV-2 single variants
- 485 **correlates with higher case fatality rates in seven EMR countries.** Scatter plots showing
- 486 percentages of each of the top ten represented substitutions with cumulative CFR as of 1 January 2021 B. Beaman's correlation coefficient
- 487 2021. R, Pearson's correlation coefficient.
- 488 Figure 6. The 'D614G & P323L' double variant is predominant in select EMR countries,
- 489 **but does not correlate with increased fatality.** (A) Percentages of Wuhan-like, S_D614G only,
- 490 NSP_P323L only and 'D614G & P323L' double variants in eight EMR countries. (B)
- 491 Distribution of the 'D614 & P323L' variant based on age groups in top four represented EMR
- 492 countries. (C) Scatter plots showing correlation of three variants with CFR in seven EMR
- 493 countries. R, Pearson's correlation coefficient.

494 Figure 7. Temporal distribution and fatality correlation of the 'D614G & P323L' double

- 495 variant with CFR in each of the top four represented EMR Countries. (A) Time-based
- 496 evolution of double variant percentages and CFR in Saudi Arabia, UAE, Oman and Egypt. (B)
- 497 Scatter plots showing correlations of the 'D614G & P323L' double variant with CFR over select
- 498 months of pandemic life in the top four represented EMR countries. R, Pearson's correlation
- 499 coefficient.

500 Supplementary Figure 1. Genome length of available EMR sequences. Sequence size

501 distribution (%) of available EMR sequences in two categories: <5000 bp and >25000 bp.

- 502 Supplementary Figure 2. Correlation between the 'D614G & P323L' double variant with
- 503 **CFR over eight months of the pandemic.** Scatter plots showing cumulative percentages of the
- double variant in seven EMR countries versus respective CFR as of the end of each month,
- 505 March through September and November. R, Pearson's correlation coefficient.



UAE

Spike_D614G 73% NSP12 P323L 72% N G204R 64% N_R203K 64% NS8_L84S 20% N_S202N 20% NSP6_M86I 18% NSP3 V12091 18% NS8_E92K 17% Spike_E583D 8%

Bahrain



Saudi Arabia



Iran



Jordan



Palestine



Pakistan



Lebanon



NSP6_L37F
NSP2_V198I
NSP2_R27C
NSP4_M33I
Spike_D614G
NSP12_P323L

Oman

Egypt



















D



Percentage of Variant

60

40

0

20

80

100

С



UAE

Oman

Egypt



Wuhan-like

50

0

Saudi

Arabia



Percentage of Variant

20

0

	40	60	80	100
	12	TC.	<i>.</i>]	
				_
_				
_				
			_	-





NS3_Q57H



0

1.5

Morocco

2

Oman

1

CFR (%)

Palestine

Bahrain

0.5

0

0

0

N_R203K

Jordan ₀ ···/	Saudi Arabia
<u> </u>	Morocco
1.5	2

Oman

1

CFR (%)

Palestine

Bahrain

0

0

0

0.5



С

D614G only

P323L only





CFR (%)



В



Saudi Arabia

Jordan



—D614G & P323L ••••• CFR

Oman